SMC Ultra-Orphan Medicines Pathway
A special process used in Scotland to assess and temporarily fund medicines for extremely rare conditions, where long-term evidence isn't yet available. It considers both clinical and broader patient and societal benefits over a three-year period while more data is collected.
At a glance
Use when
Assessing medicines for conditions with prevalence ≤1 in 50,000, especially when clinical evidence is sparse but potential benefit is high.
Avoid when
Evaluating treatments for common conditions or when robust long-term efficacy and safety data are already available.
Inputs
Clinical trial data (often limited), natural history of disease, patient and clinical input, economic model with uncertainty analysis, proposed managed access or evidence generation plan.
Outputs
Interim reimbursement decision with conditions, requirements for post-launch data collection, final recommendation after evidence review.
How it works
A distinct appraisal pathway by the Scottish Medicines Consortium (SMC) introduced in April 2019 for medicines targeting ultra-orphan conditions (prevalence ≤1 in 50,000). It employs a broad value framework encompassing the severity of the condition, clinical and non-clinical benefits, cost-effectiveness, wider societal impact, and NHS budget implications. Offers interim reimbursement for up to three years to allow evidence generation through managed access or registries.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Patient and Social Aspects
- Assumptions
- That early access to promising therapies for ultra-rare conditions is justified despite high uncertainty, and that robust post-marketing evidence generation can mitigate initial data gaps.
- Strengths
- Enables access to life-changing treatments for very small patient groups; incorporates patient and societal values; flexible approach to uncertainty; supports evidence development in real-world settings.
- Limitations
- Relies on uncertain long-term data; potential for high cost per patient; challenges in monitoring and enforcing evidence generation; limited generalizability of findings.
- Also known as
- SMC Ultra-Orphan Pathway, Ultra-Orphan Appraisal Pathway (SMC)
Questions this answers
- › Is the medicine effective for an ultra-rare condition where evidence is limited?
- › What is the broader value of the medicine beyond clinical outcomes, including patient and caregiver impact?
- › Can the medicine be considered cost-effective under high uncertainty and low patient numbers?
- › How will the medicine affect NHS resources and service delivery?
- › What evidence is needed post-launch to confirm long-term benefits and cost-effectiveness?
- › Should the medicine be recommended for interim funding while more data is collected?
References & sources
- websitescottishmedicines.org.uk ↗
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.